The drug is indicated for those patients who were previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Original Article: FDA Approves TAS-102 for Treating Adults With Gastric/GEJ Cancer